Similar articles

• Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy.

  Atluri P, Liao GP, Panlilio CM, Hsu VM, Leskowitz MJ, Morine KJ, Cohen JE, Berry MF, Suarez EE, Murphy DA, Lee WM, Gardner TJ, Sweeney HL, Woo YJ. Atluri P, et al. Ann Thorac Surg. 2006 May;81(5):1728-36. doi: 10.1016/j.athoracsur.2005.12.015. Ann Thorac Surg. 2006. PMID: 16631663
• Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction.

  Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Segers VF, et al. Circulation. 2007 Oct 9;116(15):1683-92. doi: 10.1161/CIRCULATIONAHA.107.718718. Epub 2007 Sep 17. Circulation. 2007. PMID: 17875967
• An SDF-1 trap for myeloid cells stimulates angiogenesis.

  Ruiz de Almodovar C, Luttun A, Carmeliet P. Ruiz de Almodovar C, et al. Cell. 2006 Jan 13;124(1):18-21. doi: 10.1016/j.cell.2005.12.023. Cell. 2006. PMID: 16413476 Review.
• Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties.

  Pelus LM, Fukuda S. Pelus LM, et al. Exp Hematol. 2006 Aug;34(8):1010-20. doi: 10.1016/j.exphem.2006.04.004. Exp Hematol. 2006. PMID: 16863907 Review.
• Mesenchymal stem/stromal cells (MSC) transfected with stromal derived factor 1 (SDF-1) for therapeutic neovascularization: enhancement of cell recruitment and entrapment.

  Zhou B, Han ZC, Poon MC, Pu W. Zhou B, et al. Med Hypotheses. 2007;68(6):1268-71. doi: 10.1016/j.mehy.2006.09.066. Epub 2007 Jan 2. Med Hypotheses. 2007. PMID: 17197116